Taken tattaunawa zai kasance Novavax 'COVID-NanoFlu V Combination Vaccine, wanda ya haɗu da kamfanin recombinant nanoparticle protein-based protein-based COVID-19 da NanoFlu candidates' yan takarar allurar rigakafi tare da Matrix-M ™ adjuvant a cikin tsari guda.
Bayanin zaman kamar haka:
| Rana: Laraba, 20 ga Oktoba, 2021 |
| Lokaci: 11:30 na safe - 12:00 na yamma Lokacin Tsakiyar Turai (CET) / |
| 5:30 na safe - 6:00 na yamma Lokacin Hasken Rana na Gabas (EDT) |
| Taken: Sabunta kan allurar Novavax 'NanoFlu da haɓaka allurar rigakafin COVID-19-NanoFlu |
| Mahalarta Novavax: Vivek Shinde, MD, Mataimakin Shugaban ƙasa, Ci gaban Magunguna |
Dandalin fasahar recombinant na kamfani yana haɗa ƙarfi da saurin injiniyan kwayoyin halitta don samar da ingantattun samfuran nanoparticles waɗanda aka tsara don magance buƙatun lafiyar duniya na gaggawa. Novavax yana gudanar da gwajin asibiti na ƙarshen-lokaci don NVX-CoV2373, ɗan takarar rigakafin cutar kan SARS-CoV-2, kwayar cutar da ke haifar da COVID-19. NanoFlu ™, allurar rigakafin cutar nanoparticle ta huɗu, ta sadu da duk maƙasudi na farko a cikin mahimmancin gwajin asibiti na 3 a cikin tsofaffi. Duka 'yan takarar allurar rigakafin sun hada da Novavax' Matrix-M ™ na saponin na saponin don inganta martanin rigakafi da kuma tayar da manyan matakan rigakafin garkuwar jiki.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- NanoFlu™, allurar rigakafin mura na nanoparticle, ya gamu da dukkan maƙasudai na farko a cikin babban gwaji na asibiti na Phase 3 a cikin manya.
- Dandalin fasahar recombinant mallakar kamfani ya haɗu da ƙarfi da saurin injiniyan kwayoyin halitta don samar da ingantaccen nanoparticles na rigakafi waɗanda aka ƙera don magance buƙatun lafiya na duniya cikin gaggawa.
- Novavax tana gudanar da gwaje-gwajen asibiti na ƙarshen zamani don NVX-CoV2373, ɗan takararta na rigakafi da SARS-CoV-2, kwayar cutar da ke haifar da COVID-19.
